International Biotechnology (LON:IBT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

International Biotechnology (LON:IBT)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 686.23 ($8.57) and traded as high as GBX 710 ($8.87). International Biotechnology shares last traded at GBX 710 ($8.87), with a volume of 48,839 shares trading hands.

International Biotechnology Stock Up 0.8 %

The company has a debt-to-equity ratio of 9.66, a current ratio of 0.46 and a quick ratio of 0.32. The stock has a market capitalization of £264.63 million, a P/E ratio of 1,491.67 and a beta of 0.21. The firm has a 50-day simple moving average of GBX 693.87 and a 200 day simple moving average of GBX 686.65.

International Biotechnology (LON:IBT) last posted its earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) EPS for the quarter. International Biotechnology had a net margin of 75.33% and a return on equity of 6.25%. On average, equities research analysts forecast that International Biotechnology will post 0.9435943 EPS for the current year.

International Biotechnology Increases Dividend

The company also recently announced a dividend, which was paid on Friday, January 24th. Shareholders of record on Thursday, December 19th were given a GBX 15.56 ($0.19) dividend. The ex-dividend date was Thursday, December 19th. This is an increase from International Biotechnology’s previous dividend of $14.50. This represents a yield of 2.21%. International Biotechnology’s dividend payout ratio (DPR) is currently 6,041.67%.

Insider Activity

In related news, insider Katherine Cornish-Bowden purchased 1,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of GBX 713 ($8.90) per share, with a total value of £10,695 ($13,353.73). Insiders own 4.18% of the company’s stock.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.